<DOC>
	<DOC>NCT01142323</DOC>
	<brief_summary>The purpose of this study is to determine whether fenofibrate is safe and effective in the treatment primary sclerosing cholangitis (PSC).</brief_summary>
	<brief_title>Fenofibrate for PSC</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis, Sclerosing</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Male and female patients of 18 to 75 years old Confirmed diagnosis of PSC including typical findings of stricturing and dilatations of the intra and/or extrahepatic biliary ducts in radiographic exam, (endoscopic retrograde cholangiopancreatography ERCP, percutaneous cholangiogram PTC or magnetic resonance cholangiopancreatography MRCP) Serum alkaline phosphatase levels elevated to at least 1.5 times the upper limit of normal. Hypersensitivity to fenofibrate Prisoners and institutionalized subjects Pregnant or nursing women Anticipated need for liver transplantation in one year Recipients of liver transplantation Recurrent variceal hemorrhage, uncontrolled encephalopathy or refractory ascites Coexisting liver diseases including autoimmune and viral hepatitis Acute or chronic renal failure, defined as glomerular filtration rate (GFR)&lt; 60 ml/min, GFR calculated using the Modification of Diet in Renal Disease (MDRF) GFR calculator Known cholecystitis Current use of statins Current use of coumadin anticoagulant therapy Previous history of, or known high risk for, venous thromboembolism,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>